Evolus (NASDAQ:EOLS) Issues Quarterly Earnings Results

Evolus (NASDAQ:EOLS) announced its earnings results on Tuesday. The company reported $0.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.09), reports. The business had revenue of $90.30 million during the quarter, compared to analyst estimates of $89.58 million.

Here are the key takeaways from Evolus’ conference call:

• Company highlights portfolio momentum — Jeuveau reached ~14% U.S. toxin share and Evolysse has >3,000 purchasing accounts with Evolysse Sculpt expected to file/receive FDA approval in Q4 and a large sampling program planned for Q2 2026.
• Solid 2025 performance and explicit 2026 targets — full‑year 2025 revenue was $297.2M (+12%)$90.3M (+14%)$327M–$337M with an expectation of full‑year profitability (low‑to‑mid single‑digit adjusted EBITDA) and 13%–15% adjusted EBITDA by 2028.
• Improved cost structure and liquidity — management rebased expenses in mid‑2025, expects non‑GAAP OpEx of $210M–$216M in 2026 (0%–3% growth), ended Q4 with $53.8M cash and access to a revolving facility plus additional debt tranches, and says it is not planning an equity raise.
• Ongoing market and policy headwinds — U.S. injectable procedural volumes declined in 2025, the filler market remains pressured, and Evolus products imported from France are currently subject to a 15% tariff (possible further tariff risk and uncertain recovery of prior tariffs), while new competitor toxin launches in 2026 could create near‑term sampling pressure.

Evolus Stock Up 29.8%

NASDAQ:EOLS traded up $1.23 during mid-day trading on Wednesday, reaching $5.36. The company’s stock had a trading volume of 4,751,815 shares, compared to its average volume of 1,194,114. Evolus has a 1 year low of $4.09 and a 1 year high of $14.60. The stock has a fifty day moving average of $5.11 and a 200-day moving average of $6.24. The firm has a market capitalization of $347.44 million, a PE ratio of -5.83 and a beta of 1.02.

Evolus News Summary

Here are the key news stories impacting Evolus this week:

• Positive Sentiment: BTIG Research reaffirmed a “buy” rating and set a $13.00 price target (~122% upside from recent levels), which can attract bullish flows and coverage-driven buying. BTIG Reaffirmation
• Positive Sentiment: Evolus raised FY2026 revenue guidance to $327M–$337M, above the Street (~$316.3M), signaling stronger top-line momentum and supporting upside to estimates. 2026 Revenue Guidance
• Positive Sentiment: Company press release highlights near-$300M 2025 revenue, sixth consecutive year of double-digit growth, and a stated expectation of sustainable profitability beginning in 2026 — a strategic narrative that supports a re-rating if execution continues. BusinessWire Results
• Positive Sentiment: Quarterly revenue of $90.3M came in slightly above analyst estimates (~$89.6M), providing a tangible beat on the top line despite mixed commentary on margins and EPS. Quarterly Results Deck
• Neutral Sentiment: Earnings call transcripts and highlights are available for detail on growth drivers (international expansion, product portfolio) and management’s cadence for profitability; useful for modeling but not an immediate catalyst on their own. Earnings Call Transcript
• Neutral Sentiment: Zacks reported EPS of $0.06 that matched its consensus — this suggests some analysts see the quarter as in-line even as revenue and guidance pushed the stock higher. Zacks EPS Report
• Neutral Sentiment: Reported short-interest data shows anomalies (zeros/NaN), indicating the published short-interest figures are unreliable right now and shouldn’t be treated as a clear supply signal. Short Interest Data
• Negative Sentiment: There are conflicting EPS reports across outlets (some note a miss vs. consensus and others report an in-line beat), creating near-term uncertainty about profitability and margins that could temper multiple expansion until numbers are reconciled. Mixed EPS Reporting

Insider Buying and Selling

In other news, insider David Moatazedi sold 10,539 shares of the business’s stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $7.15, for a total value of $75,353.85. Following the completion of the sale, the insider owned 354,388 shares in the company, valued at approximately $2,533,874.20. The trade was a 2.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 6.10% of the company’s stock.

Institutional Trading of Evolus

Hedge funds have recently modified their holdings of the company. Rhumbline Advisers raised its stake in Evolus by 2.0% in the 2nd quarter. Rhumbline Advisers now owns 85,093 shares of the company’s stock worth $784,000 after acquiring an additional 1,657 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Evolus by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock valued at $400,000 after buying an additional 1,838 shares during the last quarter. Invesco Ltd. raised its position in Evolus by 7.5% during the 2nd quarter. Invesco Ltd. now owns 34,283 shares of the company’s stock worth $316,000 after buying an additional 2,383 shares during the last quarter. Quantbot Technologies LP lifted its stake in Evolus by 15.4% during the 2nd quarter. Quantbot Technologies LP now owns 29,731 shares of the company’s stock valued at $274,000 after acquiring an additional 3,971 shares during the period. Finally, Quadrature Capital Ltd increased its stake in shares of Evolus by 29.9% in the fourth quarter. Quadrature Capital Ltd now owns 18,095 shares of the company’s stock worth $120,000 after acquiring an additional 4,168 shares during the period. 90.69% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on EOLS. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Evolus in a research report on Monday, December 22nd. BTIG Research reissued a “buy” rating and set a $13.00 target price on shares of Evolus in a research note on Wednesday. HC Wainwright cut their price target on shares of Evolus from $20.00 to $13.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Wall Street Zen upgraded shares of Evolus from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Evolus in a research report on Wednesday, December 24th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.50.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.